Triangleazenosertib (NCT05128825)
azenosertib trial for High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT05128825). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with platinum-resistant, Cyclin-E1-positive high-grade serous ovarian, fallopian-tube or peritoneal cancer after one to four treatment lines, including weekly taxane therapy. Prior bevacizumab, mirvetuximab and PARP therapy are required when eligible.
The idea: test azenosertib tablets, four hundred milligrams daily for five days, then two days off. It blocks WEE1, pushing damaged cancer cells through division. Only part 2c remains open. Researchers measure tumor response and safety. Primary platinum-refractory disease is excluded.
This phase 2 study plans 310 patients. Zentalis subsidiary K-Group, Beta sponsors thirty-four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.